Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes?

When immune cells and developing tumor cells localize to a common microenvironment, an assemblage of interactions takes place; this results in either tumor destruction by way of immunosurveillance or tumor outgrowth. These events put a functional imprint onto the emerging tumor repertoire because tumor cells arising in the presence of a fully functional immune system are less immunogenic than those that develop in the absence of immunity (i.e. in RAG2(-/-) and perforin(-/-) mice). However, other studies suggest that the immune system can also actively promote formation of certain tumors. These apparent disparate effects of immunity on tumorigenesis provide a unique model for study of the decision-making process that dictates immune function within a tumor.

[1]  Gerd Ritter,et al.  Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[2]  L. Lanier,et al.  NKG2D ligands: unconventional MHC class I-like molecules exploited by viruses and cancer. , 2003, Tissue antigens.

[3]  A. Balmain,et al.  Characterizing the Protective Component of the αβ T Cell Response to Transplantable Squamous Cell Carcinoma , 2004 .

[4]  S. Gasser,et al.  The DNA damage response arouses the immune system. , 2006, Cancer research.

[5]  D. Hanahan,et al.  Immune Enhancement of Skin Carcinogenesis by CD4+ T Cells , 2003, The Journal of experimental medicine.

[6]  F. Burnet.  The concept of immunological surveillance. , 1970, Progress in experimental tumor research.

[7]  Michael Karin,et al.  IKK/NF-κB signaling: balancing life and death – a new approach to cancer therapy , 2005 .

[8]  M. Karin.  Nuclear factor-κB in cancer development and progression , 2006, Nature.

[9]  R. Schreiber,et al.  A critical function for type I interferons in cancer immunoediting , 2005, Nature Immunology.

[10]  R. Schreiber,et al.  Interferon-γ and cancer immunoediting , 2005 .

[11]  M. Smyth,et al.  NKG2D function protects the host from tumor initiation , 2005, The Journal of experimental medicine.

[12]  M. Karin.  Nuclear factor-kappaB in cancer development and progression. , 2006, Nature.

[13]  Robert D. Schreiber,et al.  Interferons, immunity and cancer immunoediting , 2006, Nature Reviews Immunology.

[14]  R. Schreiber,et al.  Comparative analysis of regulatory and effector T cells in progressively growing versus rejecting tumors of similar origins. , 2006, Cancer research.

[15]  R. Schreiber,et al.  Interferon-gamma and cancer immunoediting. , 2005, Immunologic research.

[16]  Julia M. Lewis,et al.  The Distinct Contributions of Murine T Cell Receptor (TCR)γδ+ and TCRαβ+ T Cells to Different Stages of Chemically Induced Skin Cancer , 2003, The Journal of experimental medicine.

[17]  J. Trapani,et al.  Suppression of Lymphoma and Epithelial Malignancies Effected by Interferon γ , 2002, The Journal of experimental medicine.

[18]  Gavin P Dunn,et al.  Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. , 2006, Advances in immunology.

[19]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[20]  Roberta Castriconi,et al.  Surface NK receptors and their ligands on tumor cells. , 2006, Seminars in immunology.

[21]  R. Schreiber,et al.  IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity , 2001, Nature.

[22]  L. Klampfer,et al.  Signal transducers and activators of transcription (STATs): Novel targets of chemopreventive and chemotherapeutic drugs. , 2006, Current cancer drug targets.

[23]  Hua Yu,et al.  Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells , 2004, Nature Medicine.

[24]  Z. Trajanoski,et al.  Effector memory T cells, early metastasis, and survival in colorectal cancer. , 2005, The New England journal of medicine.

[25]  M. Karin,et al.  Inhibition of NF-κB in cancer cells converts inflammation- induced tumor growth mediated by TNFα to TRAIL-mediated tumor regression , 2004 .

[26]  H. Lawrence.  Cellular and humoral aspects of the hypersensitive states : a symposium held at the New York academy of medicine , 1959 .

[27]  Michael Karin,et al.  IKKβ Couples Hepatocyte Death to Cytokine-Driven Compensatory Proliferation that Promotes Chemical Hepatocarcinogenesis , 2005, Cell.

[28]  George Coukos,et al.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. , 2003, The New England journal of medicine.

[29]  Michael Karin,et al.  IKK/NF-kappaB signaling: balancing life and death--a new approach to cancer therapy. , 2005, The Journal of clinical investigation.

[30]  Eric J. Brown,et al.  The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor , 2005, Nature.

[31]  D. Pardoll,et al.  Does the immune system see tumors as foreign or self? , 2003, Annual review of immunology.

[32]  T. Mcclanahan,et al.  IL-23 promotes tumour incidence and growth , 2006, Nature.

[33]  M. Girardi.  Immunosurveillance and Immunoregulation by γδ T Cells , 2006 .

[34]  Alberto Mantovani,et al.  Inflammation and cancer: back to Virchow? , 2001, The Lancet.

[35]  R. Schreiber,et al.  The immunobiology of cancer immunosurveillance and immunoediting. , 2004, Immunity.

[36]  A. Hayday,et al.  Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance , 2005, Nature Immunology.

[37]  R. Schreiber,et al.  The three Es of cancer immunoediting. , 2004, Annual review of immunology.

[38]  L. Coussens,et al.  De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. , 2005, Cancer cell.

[39]  C. Yee,et al.  Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation , 2002, Nature.

[40]  I. M. Neiman,et al.  [Inflammation and cancer]. , 1974, Patologicheskaia fiziologiia i eksperimental'naia terapiia.

[41]  Eric B Haura,et al.  Mechanisms of Disease: insights into the emerging role of signal transducers and activators of transcription in cancer , 2005, Nature Clinical Practice Oncology.

[42]  L. Lanier,et al.  NKG2D-mediated Natural Killer Cell Protection Against Cytomegalovirus Is Impaired by Viral gp40 Modulation of Retinoic Acid Early Inducible 1 Gene Molecules , 2003, The Journal of experimental medicine.

[43]  J. Trapani,et al.  A fresh look at tumor immunosurveillance and immunotherapy , 2001, Nature Immunology.

[44]  M. Smyth,et al.  Innate Immune Surveillance of Spontaneous B Cell Lymphomas by Natural Killer Cells and γδ T Cells , 2004, The Journal of experimental medicine.

[45]  Carissa A. Sanchez,et al.  Genetic clonal diversity predicts progression to esophageal adenocarcinoma , 2006, Nature Genetics.

[46]  M. Smyth,et al.  NKG2D and cytotoxic effector function in tumor immune surveillance. , 2006, Seminars in immunology.

[47]  R. Weinberg,et al.  The Biology of Cancer , 2006 .

[48]  Michael Karin,et al.  NF-κB: linking inflammation and immunity to cancer development and progression , 2005, Nature Reviews Immunology.

[49]  G. Willimsky,et al.  Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance , 2005, Nature.

[50]  R. Schreiber,et al.  Cancer immunoediting: from immunosurveillance to tumor escape , 2002, Nature Immunology.

[51]  D. Hanahan,et al.  CD4+ T cell-mediated antigen-specific immunotherapy in a mouse model of cervical cancer. , 2005, Cancer research.

[52]  P. Opolon,et al.  A novel dendritic cell subset involved in tumor immunosurveillance , 2006, Nature Medicine.